- Clinician adherence to applying each manufacturer’s recommendation point.
| Variables | Applied or not | n (%) |
|---|---|---|
| Observe all patients for bradycardia for at least 6 hours; monitor pulse and blood pressure hourly. Electrocardiograms (ECGs) prior to dosing and at the end of observation period required. | Yes | 113 (80.7) |
| No | 27 (19.3) | |
| Ophthalmic examinations before and 3–4 months after start of treatment to assess for macular edema. | Yes | 22 (15.7) |
| No | 118 (84.3) | |
| Liver transaminases (aspartate transaminase and alanine transaminase) plus total bilirubin levels should be available before initiation of therapy and obtained within 6 months of Fingolimod initiation. | Yes | 77 (55.0) |
| No | 63 (45.0) | |
| Obtain complete blood cells, monitor for infection during treatment and for 2 months after discontinuation. | Yes | 12 (8.6) |
| No | 128 (91.4) |